

John C Stevenson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5220471/publications.pdf>

Version: 2024-02-01

118
papers

6,378
citations

70961

41
h-index

66788

78
g-index

119
all docs

119
docs citations

119
times ranked

5295
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Sex- and menopause-associated changes in body-fat distribution. <i>American Journal of Clinical Nutrition</i> , 1992, 55, 950-954. | 2.2 | 641 |
| 2 | Influence of age and menopause on serum lipids and lipoproteins in healthy women. <i>Atherosclerosis</i> , 1993, 98, 83-90. | 0.4 | 482 |
| 3 | Determinants of bone density in normal women: risk factors for future osteoporosis?. <i>BMJ: British Medical Journal</i> , 1989, 298, 924-928. | 2.4 | 369 |
| 4 | The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Maturitas</i> , 2014, 79, 122-132. | 1.0 | 213 |
| 5 | Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 846-853. | 1.5 | 212 |
| 6 | Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. <i>Endocrine Reviews</i> , 2017, 38, 173-188. | 8.9 | 206 |
| 7 | Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins. <i>American Journal of Obstetrics and Gynecology</i> , 1992, 166, 950-955. | 0.7 | 200 |
| 8 | Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. <i>Lancet, The</i> , 1995, 346, 89-90. | 6.3 | 200 |
| 9 | The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. <i>European Journal of Clinical Investigation</i> , 1993, 23, 466-473. | 1.7 | 180 |
| 10 | Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. <i>Climacteric</i> , 2011, 14, 302-320. | 1.1 | 176 |
| 11 | 17 β -Oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1998, 1406, 169-174. | 1.8 | 149 |
| 12 | Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. <i>European Heart Journal</i> , 2021, 42, 967-984. | 1.0 | 136 |
| 13 | Is there a menopausal metabolic syndrome?. <i>Gynecological Endocrinology</i> , 1997, 11, 341-355. | 0.7 | 122 |
| 14 | Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2019, 180, 41-50. | 1.9 | 109 |
| 15 | Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. <i>Atherosclerosis</i> , 2016, 254, 282-290. | 0.4 | 105 |
| 16 | Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. <i>Calcified Tissue International</i> , 1996, 59, 6-11. | 1.5 | 102 |
| 17 | Insulin resistance: syndrome or tendency?. <i>Lancet, The</i> , 1995, 346, 100-103. | 6.3 | 101 |
| 18 | Hormone replacement therapy with dydrogesterone and 17beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1997, 104, 298-304. | 1.1 | 95 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. <i>Maturitas</i> , 2017, 101, 23-30. | 1.0 | 94 |
| 20 | Menopause and diabetes: EMAS clinical guide. <i>Maturitas</i> , 2018, 117, 6-10. | 1.0 | 91 |
| 21 | Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide. <i>Maturitas</i> , 2018, 107, 7-12. | 1.0 | 88 |
| 22 | Effects of oral and transdermal 17 β -estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 742-747. | 1.5 | 81 |
| 23 | EMAS position statement: Predictors of premature and early natural menopause. <i>Maturitas</i> , 2019, 123, 82-88. | 1.0 | 80 |
| 24 | The Prevention of Osteoporosis Using Sequential Low-Dose Hormone Replacement Therapy with Estradiol-17 β and Dydrogesterone. <i>Osteoporosis International</i> , 2001, 12, 251-258. | 1.3 | 79 |
| 25 | A woman's journey through the reproductive, transitional and postmenopausal periods of life: Impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement. <i>Maturitas</i> , 2011, 70, 197-205. | 1.0 | 71 |
| 26 | The glycolytic pathway to coronary heart disease: A hypothesis. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 657-662. | 1.5 | 68 |
| 27 | Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). <i>Maturitas</i> , 2016, 89, 63-72. | 1.0 | 67 |
| 28 | Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. <i>Clinical Science</i> , 1992, 83, 489-494. | 1.8 | 66 |
| 29 | Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. <i>European Journal of Endocrinology</i> , 1993, 128, 259-262. | 1.9 | 66 |
| 30 | Coronary heart disease and menopause management: The swinging pendulum of HRT. <i>Atherosclerosis</i> , 2009, 207, 336-340. | 0.4 | 63 |
| 31 | Cardiovascular risk assessment in women – an update. <i>Climacteric</i> , 2016, 19, 329-336. | 1.1 | 62 |
| 32 | Premature Ovarian Insufficiency and Long-Term Health Consequences. <i>Current Vascular Pharmacology</i> , 2019, 17, 604-609. | 0.8 | 61 |
| 33 | Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. <i>British Journal of Haematology</i> , 2004, 124, 802-808. | 1.2 | 54 |
| 34 | The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis. <i>Maturitas</i> , 2017, 99, 27-36. | 1.0 | 54 |
| 35 | EMAS position statement: Testosterone replacement therapy in the aging male. <i>Maturitas</i> , 2016, 84, 94-99. | 1.0 | 53 |
| 36 | The menopausal hot flush: a review. <i>Climacteric</i> , 2017, 20, 296-305. | 1.1 | 52 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. <i>Clinical Endocrinology</i> , 2004, 60, 541-549. | 1.2 | 48 |
| 38 | Justification for the use of HRT in the long-term prevention of osteoporosis. <i>Maturitas</i> , 2005, 51, 113-126. | 1.0 | 47 |
| 39 | The WHI: the effect of hormone replacement therapy on fracture prevention. <i>Climacteric</i> , 2012, 15, 263-266. | 1.1 | 47 |
| 40 | Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. <i>Obstetrics and Gynecology</i> , 1994, 84, 222-6. | 1.2 | 47 |
| 41 | Type and route of estrogen administration. <i>Climacteric</i> , 2009, 12, 86-90. | 1.1 | 43 |
| 42 | Osteoporosis management in patients with breast cancer: EMAS position statement. <i>Maturitas</i> , 2017, 95, 65-71. | 1.0 | 42 |
| 43 | Oral ultra-low dose continuous combined hormone replacement therapy with 0.5mg 17 β -oestradiol and 2.5mg dydrogesterone for the treatment of vasomotor symptoms: Results from a double-blind, controlled study. <i>Maturitas</i> , 2010, 67, 227-232. | 1.0 | 41 |
| 44 | 17 beta-Oestradiol inhibits stimulated endothelin release in human vascular endothelial cells. <i>European Journal of Endocrinology</i> , 1997, 137, 205-208. | 1.9 | 40 |
| 45 | Cardiovascular effects of oestrogens. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2000, 74, 387-393. | 1.2 | 40 |
| 46 | EMAS recommendations for conditions in the workplace for menopausal women. <i>Maturitas</i> , 2016, 85, 79-81. | 1.0 | 40 |
| 47 | Early menopause is associated with increased risk of arterial hypertension: A systematic review and meta-analysis. <i>Maturitas</i> , 2020, 135, 74-79. | 1.0 | 40 |
| 48 | Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. <i>European Heart Journal</i> , 2006, 27, 2046-2053. | 1.0 | 35 |
| 49 | HRT and cardiovascular disease. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2009, 23, 109-120. | 1.4 | 35 |
| 50 | Cardiovascular Risk in Perimenopausal Women. <i>Current Vascular Pharmacology</i> , 2019, 17, 591-594. | 0.8 | 35 |
| 51 | Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 1. The Collaborative Reanalysis. <i>Journal of Family Planning and Reproductive Health Care</i> , 2011, 37, 103-109. | 0.9 | 34 |
| 52 | Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Table 1. <i>Journal of Family Planning and Reproductive Health Care</i> , 2012, 38, 102-109. | 0.9 | 33 |
| 53 | Hormone therapy for first-line management of menopausal symptoms: Practical recommendations. <i>Women's Health</i> , 2019, 15, 174550651986400. | 0.7 | 33 |
| 54 | HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?. <i>Human Reproduction</i> , 2006, 21, 1668-1671. | 0.4 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Oral estradiol and dydrogesterone combination therapy in postmenopausal women: Review of efficacy and safety. <i>Maturitas</i> , 2013, 76, 10-21. | 1.0 | 29 |
| 56 | Primary prevention of coronary heart disease in women. <i>Menopause International</i> , 2008, 14, 40-45. | 1.6 | 28 |
| 57 | Effects of oestrogen-only and oestrogen-progestogen replacement therapy upon circulating angiotensin I-converting enzyme activity in postmenopausal women. <i>Clinical Endocrinology</i> , 2003, 58, 30-35. | 1.2 | 26 |
| 58 | Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy. <i>Osteoporosis International</i> , 1995, 5, 344-348. | 1.3 | 25 |
| 59 | 17 β -Estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. <i>Maturitas</i> , 2001, 38, 197-203. | 1.0 | 25 |
| 60 | The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits – an attempt to interpret the Women's Health Initiative results. <i>Gynecological Endocrinology</i> , 2006, 22, 303-317. | 0.7 | 25 |
| 61 | HRT and the primary prevention of cardiovascular disease. <i>Maturitas</i> , 2007, 57, 31-34. | 1.0 | 23 |
| 62 | A model of care for healthy menopause and ageing: EMAS position statement. <i>Maturitas</i> , 2016, 92, 1-6. | 1.0 | 23 |
| 63 | Menopause-associated risk of cardiovascular disease. <i>Endocrine Connections</i> , 2022, 11, . | 0.8 | 23 |
| 64 | Current management of pelvic organ prolapse in aging women: EMAS clinical guide. <i>Maturitas</i> , 2018, 110, 118-123. | 1.0 | 21 |
| 65 | Cardiometabolic health in premature ovarian insufficiency. <i>Climacteric</i> , 2021, 24, 474-480. | 1.1 | 21 |
| 66 | Hormone replacement therapy: Review, update, and remaining questions after the women's health initiative study. <i>Current Osteoporosis Reports</i> , 2004, 2, 12-16. | 1.5 | 20 |
| 67 | Effect of postmenopausal oestradiol and dydrogesterone therapy on lipoproteins and insulin sensitivity, secretion and elimination in hysterectomised women. <i>Maturitas</i> , 2002, 42, 233-242. | 1.0 | 19 |
| 68 | Hormone replacement therapy and cardiovascular disease revisited. <i>Menopause International</i> , 2009, 15, 55-57. | 1.6 | 18 |
| 69 | Risks and benefits of hormone therapy: has medical dogma now been overturned?. <i>Climacteric</i> , 2014, 17, 215-222. | 1.1 | 18 |
| 70 | 1 and 2 mg 17 β -estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women. <i>Climacteric</i> , 2005, 8, 352-359. | 1.1 | 17 |
| 71 | The metabolic and cardiovascular consequences of HRT. <i>The British Journal of Clinical Practice</i> , 1995, 49, 87-90. | 0.2 | 17 |
| 72 | Effects of equine oestrogens on markers of vasoactive function in human coronary artery endothelial cells. <i>Molecular and Cellular Endocrinology</i> , 1999, 150, 33-37. | 1.6 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Position Statement. <i>Maturitas</i> , 2017, 100, 86-91. | 1.0 | 16 |
| 74 | HRT and breast cancer risk: a realistic perspective. <i>Climacteric</i> , 2011, 14, 633-636. | 1.1 | 15 |
| 75 | HRT and breast cancer: a million women ride again. <i>Climacteric</i> , 2020, 23, 226-228. | 1.1 | 15 |
| 76 | 7 Metabolic effects of the menopause and oestrogen replacement. <i>Bailliere's Clinical Obstetrics and Gynaecology</i> , 1996, 10, 449-467. | 0.6 | 14 |
| 77 | Long-term effects of hormone replacement therapy. <i>Lancet, The</i> , 2003, 361, 253-254. | 6.3 | 14 |
| 78 | The Metabolic Basis for the Effects of HRT on Coronary Heart Disease. <i>Endocrine</i> , 2004, 24, 239-244. | 2.2 | 13 |
| 79 | Primary Prevention of Cardiovascular Disease with HRT. <i>Women's Health</i> , 2012, 8, 63-74. | 0.7 | 13 |
| 80 | Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference. <i>Drugs in Context</i> , 2020, 9, 1-12. | 1.0 | 12 |
| 81 | Non-invasive assessment of vascular function. Paradoxical vascular response to intravenous glucose in coronary heart disease. <i>European Heart Journal</i> , 2000, 21, 39-44. | 1.0 | 10 |
| 82 | Where has WHI led us now?. <i>Maturitas</i> , 2004, 48, 1-2. | 1.0 | 10 |
| 83 | Prevention of osteoporosis: one step forward, two steps back. <i>Menopause International</i> , 2011, 17, 137-141. | 1.6 | 10 |
| 84 | Recommendations on the management of fragility fracture risk in women younger than 70 years. <i>Gynecological Endocrinology</i> , 2012, 28, 770-786. | 0.7 | 10 |
| 85 | Thiazide diuretics, β -blockers, and coronary heart disease. <i>Lancet, The</i> , 1990, 335, 1534-1535. | 6.3 | 9 |
| 86 | Misrepresentation of the risk of ovarian cancer among women using menopausal hormones. Spurious findings in a meta-analysis. <i>Maturitas</i> , 2015, 81, 323-326. | 1.0 | 8 |
| 87 | Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β -estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms. <i>Maturitas</i> , 2020, 139, 20-26. | 1.0 | 8 |
| 88 | Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, high-density lipoprotein subfractions and apolipoproteins in postmenopausal women in a two-year, randomized, double-blind, placebo-controlled trial. <i>Clinical Endocrinology</i> , 2020, 92, 303-311. | 1.2 | 7 |
| 89 | Effects of tibolone or continuous combined oestradiol/norethisterone acetate on glucose and insulin metabolism. <i>Clinical Endocrinology</i> , 2013, 78, 297-302. | 1.2 | 6 |
| 90 | The impact of bone loss in women with endometriosis. <i>International Journal of Gynecology and Obstetrics</i> , 1995, 50, S11-S15. | 1.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Metabolic effects of hormone replacement therapy. The Journal of the British Menopause Society, 2004, 10, 157-161. | 1.3 | 5 |
| 92 | Bisphosphonates and Atypical Femoral Shaft Fractures. New England Journal of Medicine, 2011, 365, 377-377. | 13.9 | 5 |
| 93 | A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity. The Journal of the British Menopause Society, 2006, 12, 8-10. | 1.3 | 4 |
| 94 | Coronary heart disease in women. New England Journal of Medicine, 2000, 343, 1891; author reply 1892-3. | 13.9 | 3 |
| 95 | Helping women make the right HRT choice. Practice Nursing, 2005, 16, 73-78. | 0.1 | 2 |
| 96 | Does estrogen therapy reduce coronary artery calcification in postmenopausal women?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 654-655. | 3.3 | 2 |
| 97 | Cardiovascular disease in women. Menopause International, 2008, 14, 5-5. | 1.6 | 2 |
| 98 | Long-term benefits and risks of HRT (Section 11): Cardiovascular disease. Post Reproductive Health, 2016, 22, 80-82. | 0.3 | 2 |
| 99 | The Influence of Sex Steroids on Affairs of the Heart. ISGE Series, 2014, , 225-231. | 0.2 | 2 |
| 100 | Hormone replacement therapy and cardiovascular disease. The Obstetrician and Gynaecologist, 2005, 7, 1-4. | 0.2 | 1 |
| 101 | Conflicts of interest, smoke and mirrors. Climacteric, 2015, 18, 348-349. | 1.1 | 1 |
| 102 | BMS consensus statement for primary prevention of coronary heart disease in women. Post Reproductive Health, 2019, 25, 64-69. | 0.3 | 1 |
| 103 | Interventions for Osteoporosis. , 2007, , 351-375. | | 1 |
| 104 | Are changes in lipoproteins during HRT important?. British Journal of Obstetrics and Gynaecology, 1996, 103 Suppl 13, 39-43; discussion 43-4. | 0.9 | 1 |
| 105 | FemostonÂ®, menopause and the cardiovascular system. Gynecological Endocrinology, 1996, 10, 118-118. | 0.7 | 0 |
| 106 | Late prevention of hip fractures with hormone replacement therapy. Osteoporosis International, 1996, 6, 64-67. | 1.3 | 0 |
| 107 | Breast cancer and HRT: general practice must not pick up the wrong pieces. Maturitas, 2003, 46, 109-110. | 1.0 | 0 |
| 108 | Metabolic consequences of the menopause. Menopause International, 2007, 13, 196-197. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | An Atlas of Osteoporosis. , 2007, , . | | 0 |
| 110 | Long-term benefits and risks of HRT (Section 11): Osteoporosis. Post Reproductive Health, 2016, 22, 92-94. | 0.3 | 0 |
| 111 | The Effect of Menopause and HRT on Coronary Heart Disease. ISGE Series, 2018, , 187-193. | 0.2 | 0 |
| 112 | The True Risks of HRT. ISGE Series, 2018, , 245-252. | 0.2 | 0 |
| 113 | Prevention and treatment of osteoporosis in women. Post Reproductive Health, 2018, 24, 167-170. | 0.3 | 0 |
| 114 | Premature Ovarian Insufficiency: Practical Management Approaches. ISGE Series, 2019, , 143-153. | 0.2 | 0 |
| 115 | David McKay Hart MD, FRCS (Glasgow), FRCOG (1936â€“2020). Post Reproductive Health, 2021, 27, 126-127. | 0.3 | 0 |
| 116 | David McKay Hart, MD, FRCS (Glasgow), FRCOG. Climacteric, 2021, 24, 421-421. | 1.1 | 0 |
| 117 | Is It Safe to Prevent and Treat Postmenopausal Osteoporosis?. ISGE Series, 2014, , 207-214. | 0.2 | 0 |
| 118 | Effects of weight changes on the bone. Climacteric, 2012, 15, 98-9. | 1.1 | 0 |